(UroToday.com) At the 2026 European Society for Medical Oncology (ESMO) Annual Congress, Dr. Laurence Albiges and colleagues presented the study design of LUTEON, an ongoing, randomized phase III ...

Radical cystectomy remains a major operation even at experienced centers and with robotic surgical techniques. Data from the ...

The 2026 ESMO annual meeting featured a prostate cancer session and a presentation by Dr. Mehdi Bsilat discussing the impact ...

Most CTC-evaluable patients in TALAPRO-2 had relatively low CTC burden at baseline, with 81.5% having <5 CTCs/7.5 mL and 65.3 ...

The 2026 ESMO annual meeting featured a rapid oral session and a discussant presentation by Dr. Alison Reid discussing three ...

(UroToday.com) The 2026 European Society of Medical Oncology (ESMO) Annual Congress held the session: Genitourinary tumour, ...

A total of 25 patients who received ≥2 cycles of toripalimab combined with TIP chemotherapy were enrolled. The objective response rate was 84.0%, with 2 patients achieving complete response and 19 ...

This analysis included 58 patients treated with gemcitabine intravesical system monotherapy in the SunRISe-1 cohort who had ...

The therapeutic landscape for metastatic hormone-sensitive prostate cancer (mHSPC) has changed significantly over the last decade with the introduction of combination strategies. However, recent ...

Andrea Apolo discusses three nectin-4 ADC trials. EV-302's 3.5-year follow-up showed median overall survival of 33.6 months with enfortumab vedotin plus pembrolizumab, and 30% of patients achieved ...

Lutetium-177-PSMA radioligand therapy ( [177Lu] Lu-PSMA) is an emerging targeted treatment for metastatic castration-resistant prostate cancer (mCRPC). We evaluated the comparative efficacy, safety, ...

To date, no head-to-head comparisons of apalutamide versus darolutamide have been reported for metastatic castration-sensitive prostate cancer (mCSPC). This study compared prostate-specific antigen ...